3 Healthcare Mutual Funds Poised For A Surge

By | May 19, 2015

Scalper1 News

The healthcare sector is coming off a strong Q1 of 2015, with over 80% of the companies in the sector beating earnings estimates. The recent success of this sector is partially the result of the Affordable Care Act. Another positive for this sector is that the demand for such services usually remains unchanged even during an economic downturn and investments in the sector provide sufficient protection to the capital invested. Healthcare mutual funds provide the perfect avenue for investors looking to invest in this sector. Below we will share with you 3 top healthcare mutual funds. Each has earned either a Zacks #1 Rank (Strong Buy) or a Zacks #2 Rank (Buy) as we expect these mutual funds to outperform their peers in the future. VALIC Company I Health Sciences (MUTF: VCHSX ) invests a majority of its assets in common stocks of healthcare products, medicine or life sciences related companies. VCHSX focuses mainly on investing in large and mid-cap companies. A maximum of 35% of VCHSX’s assets is invested foreign companies. The VALIC Company I Health Sciences fund has returned 46.2% over the past one year. Taymour R. Tamaddon is the fund manager and has managed VCHSX since 2013. Fidelity Select Health Care Portfolio (MUTF: FSPHX ) seeks capital growth over the long run. FSPHX invests a lion’s share of its assets in companies involved in designing, manufacturing and selling of healthcare products and services. FSPHX invests in companies throughout the globe. The Fidelity Select Health Care Portfolio is non-diversified fund and has returned 40.6% over the past one year. FSPHX has an expense ratio of 0.74% as compared to category average of 1.37%. Fidelity Select Biotechnology Portfolio (MUTF: FBIOX ) invests a lion’s share of its assets in companies primarily involved in research, development, manufacture, and distribution of various biotechnological products. Factors such as financial strength and economic condition are considered to invest in companies located all over the world. The Fidelity Select Biotechnology Portfolio is non-diversified fund and has returned 59.7% over the past one year. As of March 2015, this fund held 214 issues with 8.16% of its assets invested in Biogen Inc. Original Post Share this article with a colleague Scalper1 News

Scalper1 News